drugset / Trial / NCT04268394
A Study to Evaluate Potential Cytochrome P450 and Transporter Protein Interactions With CC-99677
RandomizedParallel-groupOpen-labelTreatment
Summary
It is a phase 1, open-label, single-center, three-part study to assess the safety, tolerability, and pharmacokinetics of multiple doses of CC-99677 administered alone or in combination with either methotrexate and sulfasalazine; itraconazole, rifampin, midazolam, or a cocktail of digoxin, metformin, and rosuvastatin in healthy subjects
Timeline
- Start
- 2020-03-13
- Primary completion
- 2021-06-02
- Completion
- 2021-06-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Digoxin | Other / unclassified | 0.25 mg | — |
| Subject | GAMCEMETINIB | Small molecule | — | — |
| Subject | Itraconazole | Small molecule | 200 mg | — |
| Subject | Metformin | Small molecule | 500 mg | — |
| Subject | Methotrexate | Small molecule | 7.5 mg | — |
| Subject | Midazolam | Small molecule | 2 mg | — |
| Subject | Rifampin | Small molecule | 600 mg | — |
| Subject | Rosuvastatin | Small molecule | 10 mg | — |
| Subject | Sulfasalazine | Small molecule | 1000 mg | — |
Indications
No indication recorded.